- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Sharon Phares Outlines Her Priorities in New NPC Position
Sharon Phares, PhD, MPH, discussed her new appointment as the chief scientific officer of the National Pharmaceutical Council (NPC) and her main priorities in honor of Women's Health Month.
During the Academy of Managed Care Pharmacy's Annual Meeting, Sharon Phares, PhD, MPH, discussed her new appointment as the chief scientific officer of the National Pharmaceutical Council (NPC) and her main priorities in honor of Women's Health Month.
Transcript
In your new role with the National Pharmaceutical Council, what will be your main areas of focus?
We have 3 strategic priorities. The first is looking at issues around the cost of pharmaceuticals and the supply chain. The second, looking at value, so HTA [health technology assessments] sort of issues. And then last, but not least, the most important is looking at issues that inform patient access and affordability.
Understanding TB Symptoms, Spread, Treatment Amid Kansas City Outbreak
February 13th 2025In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Addressing the Bidirectional Impact of Schizophrenia and Substance Use Disorders
February 8th 2025Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and substance use disorders in an interview.
Read More
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
February 7th 2025Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Read More
